Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations

January 2009
BMC Structural Biology;2009, Vol. 9, p58
Academic Journal
No abstract available.


Related Articles

  • Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia. Inami, M.; Yamaguchi, H.; Hasegawa, S.; Mitamura, Y.; Kosaka, F.; Kobayashi, A.; Kimura, S.; Dan, K.; Inokuchi, K. // Leukemia (08876924);Jan2008, Vol. 22 Issue 1, p216 

    A letter to the editor is presented about the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.

  • High Percentage of JAK2 Exon 12 Mutation in Asian Patients With Polycythemia Vera. Yu-Min Yeh; Yi-Lin Chen; Hsieh-Yin Cheng; Wu-Chou Su; Nan-Haw Chow; Tsai-Yun Chen; Chung-Liang Ho // American Journal of Clinical Pathology;Aug2010, Vol. 134 Issue 2, p266 

    We examined the occurrence of JAK2V617F and JAK2 exon 12 mutations in a clinical cohort of polycythemia vera (PV) in Taiwan. Of 22 patients with PV, 17 (77%) had the V617F mutation, and all 5 V617F-negative patients (23%) had the exon 12 mutation. We found 3 different exon 12 mutations: 3...

  • EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. Cheng, Chao; Wang, Rui; Li, Yuan; Pan, Yunjian; Zhang, Yang; Li, Hang; Zheng, Difan; Zheng, Shanbo; Shen, Xuxia; Sun, Yihua; Chen, Haiquan // Scientific Reports;9/11/2015, p13959 

    Our aim was to investigate the clinical and pathologic characteristics of the epidermal growth factor receptor (EGFR) exon 18 mutations in East Asian lung adenocarcinomas patients. A total of 1,201 lung adenocarcinomas were analyzed for mutation in EGFR. Clinical and pathologic characteristics...

  • High resolution melting for mutation scanning of TP53 exons 5-8. Krypuy, Michael; Ashour Ahmed, Ahmed; Etemadmoghadam, Dariush; Hyland, Sarah J.; deFazio, Anna; Fox, Stephen B.; Brenton, James D.; Bowtell, David D.; Dobrovic, Alexander; 7 // BMC Cancer;2007, Vol. 7, p1 

    Background: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53 often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value. We therefore evaluated the use of high...

  • Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations. Hsueh, Yuan-Shuo; Lin, Chih-Lung; Chiang, Nai-Jung; Yen, Chueh-Chuan; Li, Chien-Feng; Shan, Yan-Shen; Ko, Ching-Huai; Shih, Neng-Yao; Wang, Ling-Mei; Chen, Ting-Shou; Chen, Li-Tzong // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Advanced gastrointestinal stromal tumors (GIST), a KIT oncogene-driven tumor, on imatinib mesylate (IM) treatment may develop secondary KIT mutations to confer IM-resistant phenotype. Second-line sunitinib malate (SU) therapy is largely ineffective for IM-resistant GISTs with secondary exon 17...

  • Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Toms, Angela V; Deshpande, Anagha; McNally, Randall; Jeong, Youngjee; Rogers, Julia M; Kim, Chae Un; Gruner, Sol M; Ficarro, Scott B; Marto, Jarrod A; Sattler, Martin; Griffin, James D; Eck, Michael J // Nature Structural & Molecular Biology;Oct2013, Vol. 20 Issue 10, p1221 

    The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equivalent mutation in Jak1 (V658F) is found in T-cell leukemias. Crystal structures of wild-type and V658F-mutant human Jak1 pseudokinase reveal a conformational switch that remodels a linker segment...

  • Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms? Vorechovsky, I; Jones, A V; Cross, N C P // Leukemia (08876924);Sep2013, Vol. 27 Issue 9, p1930 

    A letter to the editor is presented regarding the mutation cluster of Janus kinase 2 (JAK2) exon 12 in myeloproliferative neoplasm (MPN) patients.

  • Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. IMPROTA, GIUSEPPINA; PETTINATO, ANGELA; GIERI, STEFANIA; SCANDURRA, GIUSEPPA; SKOVRIDER-RUMINSKI, WOJCIECH; HØGDALL, ESTRID; FRAGGETTA, FILIPPO // Oncology Letters;Jan2016, Vol. 11 Issue 1, p393 

    Epidermal growth factor receptor (EGFR) plays a significant role in non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer worldwide. Therefore, EGFR may be a useful molecular target for personalized therapy utilizing tyrosine kinase inhibitors (TKIs). Somatic activating EGFR...

  • Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Vidaurreta, M.; Maestro, M. L.; Sanz-Casla, M. T.; Rafael, S.; Veganzones, S.; de la Orden, V.; Cerdán, J.; Arroyo, M.; Torres, A. // International Journal of Colorectal Disease;Jun2008, Vol. 23 Issue 6, p581 

    Gene p53 alteration is a genetic event described in the progression from adenoma to colorectal carcinoma. Most of the p53 mutations occur in exons 5 to 8 in highly preserved regions and in the three main structural domains of the p53 protein. It is possible that mutations affecting different...

  • Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Butcher, C. M.; Hahn, U.; To, L. B.; Gecz, J.; Wilkins, E. J.; Scott, H. S.; Bardy, P. G.; D'Andrea, R. J. // Leukemia (08876924);Apr2008, Vol. 22 Issue 4, p870 

    A letter to the editor is presented that discusses the two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics